Allurion Technologies Inc. (ALUR)
NYSE NYSE Primary 
4 Medical Product Stocks to Watch From a Challenging Industry
The Zacks Medical products industry sees steady demand, but macro headwinds keep growth under pressure in 2025. BSX, PODD, BLFS and ALUR reflect the favorable fundamentals.
Allurion Technologies Inc. (ALUR) Q3 2025 Earnings Call Transcript
Allurion Technologies Inc. ( ALUR ) Q3 2025 Earnings Call November 12, 2025 8:30 AM EST Company Participants Tara Brady Shantanu Gaur - Co-Founder, CEO, President, Principal Financial & Accounting Officer and Director Conference Call Participants Joshua Jennings - TD Cowen, Research Division Presentation Operator Hello, and thank you for standing by. My name is Mark, and I will be your conference operator today.
Allurion Technologies, Inc. (ALUR) Reports Q2 Loss, Misses Revenue Estimates
Allurion Technologies, Inc. (ALUR) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to earnings of $0.25 per share a year ago.
4 Medical Product Stocks to Watch From a Challenging Industry
The U.S. government's tariff imposition, especially on China, is likely to keep supply chains under pressure for the Zacks Medical Products industry. PODD, MGNX, CLRB and ALUR reflect the favorable fundamentals.
Allurion Technologies Inc. (ALUR) Q1 2025 Earnings Call Transcript
Allurion Technologies Inc. (NYSE:ALUR ) Q1 2025 Earnings Conference Call May 14, 2025 8:30 AM ET Company Participants Tara Brady - Interim CFO Shantanu Gaur - Founder and CEO Conference Call Participants Jason Wittes - ROTH Capital Partners Josh Jennings - TD Cowen Keay Nakae - Chardan Capital Mike Toomey - Jefferies Operator Hello, everyone, and welcome to Allurion First Quarter Earnings Call. All lines have been placed on mute to prevent any background noise.
Allurion Technologies, Inc. (ALUR) Q1 Earnings Beat Estimates
Allurion Technologies, Inc. (ALUR) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Estimate of a loss of $1.53 per share. This compares to earnings of $2.75 per share a year ago.
4 Medical Product Stocks to Buy From a Challenging Industry
The U.S. government's tariff imposition, especially on China, is likely to keep supply chains under pressure for the Zacks Medical Products industry. PODD, MGNX, CLRB and ALUR are likely to gain from the favorable factors.
Allurion Technologies Inc. (ALUR) Q4 2024 Earnings Call Transcript
Allurion Technologies Inc. (NYSE:ALUR ) Q4 2024 Earnings Conference Call March 26, 2025 8:30 AM ET Company Participants Mike Cavanaugh - Investor Relations Shantanu Gaur - Founder and Chief Executive Officer Conference Call Participants Matthew Taylor - Jefferies Josh Jennings - TD Cowen Jason Wittes - ROTH Capital Partners Keay Nakae - Chardan Capital Operator Hello, everyone, and welcome to Allurion Fourth Quarter Earnings Call. Please note that this call is being recorded.
Allurion Technologies, Inc. (ALUR) Reports Q4 Loss, Lags Revenue Estimates
Allurion Technologies, Inc. (ALUR) came out with a quarterly loss of $7 per share versus the Zacks Consensus Estimate of a loss of $5. This compares to loss of $15.75 per share a year ago.
How Much Upside is Left in Allurion Technologies, Inc. (ALUR)? Wall Street Analysts Think 374.67%
The mean of analysts' price targets for Allurion Technologies, Inc. (ALUR) points to a 374.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Allurion Technologies Shares Are Up Today: What's Going On?
Allurion Technologies ALUR shares are moving higher Friday, potentially in response to the company's Thursday announcement of a planned clinical study to evaluate the combination of its Allurion Program with GLP-1 agonists.
Allurion Stock Triples on Plan to Test Gastric Balloon With Obesity Drugs
Shares of Allurion Technologies (ALUR) tripled Friday as the maker of the Allurion Gastric Balloon weight-loss device looked to take advantage of the booming obesity drug market.
